HCWB HCW Biologics Inc.
Price Chart
Executive Summary
Two HCWB insiders (Director Garrett and CFO Byam) made open-market purchases totaling $270K on May 22, 2026, at $1.405/share. This cluster follows a dilutive $3.6M private placement (May 21) and a Q1 earnings report showing a $3.5M net income swing but a going-concern warning and Nasdaq delisting appeal. The insider buying is a strong bullish signal given the micro-cap distress context, but the company's fundamental outlook remains precarious.
Key Financial Metrics
Actionable Insight
The cluster of insider buying at $1.405, just above the $1.28 private placement price and after a going-concern warning, is a high-conviction signal that insiders see value. However, the company faces imminent delisting and cash constraints. Traders should monitor for a reverse stock split or further financing announcements. The buying may front-run positive news (e.g., a partnership or license deal), but the risk of equity overhang from the ELOC starting June 15 is real.
Key Facts
- Director Garrett Scott T purchased 177,936 shares for $250,000 at $1.405/share on May 22, 2026.
- CFO Rebecca Byam purchased 14,235 shares for $20,000 at $1.405/share on May 22, 2026.
- Total insider buying of $270K represents ~1.5% of HCWB's $18M market cap.
- The purchases occurred one day after a $3.6M dilutive private placement (2.85M shares + warrants at $1.28/share).
- Q1 2026 earnings (May 14) showed $3.5M net income vs. a $2.2M loss, driven by $6.5M Trimmune license revenue, but reiterated going-concern doubt and Nasdaq delisting risk.
- The company had only $1.2M cash on hand as of Q1 2026.
Financial Impact
Insider purchases of $270K represent ~1.5% of market cap, a material signal for a micro-cap biotech.
Risk Factors
- Nasdaq delisting risk remains active; minimum bid price non-compliance not yet resolved.
- Only $1.2M cash on hand; the $3.6M private placement provides a short runway but may not be sufficient.
- The existing ELOC with Square Gate Capital (starting June 15) could cause further dilution.
- The company's going-concern status suggests a high probability of additional dilutive financing or restructuring.
Market Snapshot
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-HCWB-1779924390748 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 1, 2026
4d ago
|
8-K
| $2.07 $1.79 | ▲ +13.53% | ▲ +13.67% | $1.63 (+21.26%) |
|
May 27, 2026
8d ago
|
Insider Cluster
| $2.09 $1.98 | ▼ −5.26% | ▼ −5.50% | $1.63 (−22.01%) |
|
May 27, 2026
9d ago
|
8-K
| $1.94 $2.09 | ▲ +7.73% | ▲ +7.18% | $1.63 (−15.98%) |
|
May 21, 2026
15d ago
|
8-K
| $2.89 $2.62 | ▲ +9.34% | ▲ +9.93% | $1.63 (+43.60%) |
|
May 21, 2026
15d ago
|
Press Release
| $2.58 $2.89 | ▼ −12.02% | ▼ −11.57% | $1.63 (+36.82%) |
|
May 14, 2026
22d ago
|
8-K
| — | awaiting T+1 | — | — |
|
May 14, 2026
22d ago
|
Press Release
| — | awaiting T+1 | — | — |
|
May 14, 2026
22d ago
|
Press Release
| $0.3370 $1.22 | ▲ +262.02% | ▲ +263.24% | $1.63 (+383.68%) |
|
Apr 30, 2026
5w ago
|
8-K
| — | awaiting T+1 | — | — |
|
Apr 24, 2026
6w ago
|
S-1/A
| $0.4390 $0.4000 | ▼ −8.88% | ▼ −8.40% | $1.63 (+271.30%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access